share_log

Transcode Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

SEC ·  May 21 04:01

Summary by Moomoo AI

TransCode Therapeutics, Inc. (TransCode) has announced the filing of a DEFR14A form with the United States Securities and Exchange Commission (SEC), which includes a Proxy Statement and an amendment to the company's Definitive Proxy Statement on Schedule 14A. The Proxy Statement, filed on May 20, 2024, outlines proposals for the upcoming 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The key proposals include the election of four directors, approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split of common stock at a ratio ranging from 1:2 to...Show More
TransCode Therapeutics, Inc. (TransCode) has announced the filing of a DEFR14A form with the United States Securities and Exchange Commission (SEC), which includes a Proxy Statement and an amendment to the company's Definitive Proxy Statement on Schedule 14A. The Proxy Statement, filed on May 20, 2024, outlines proposals for the upcoming 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The key proposals include the election of four directors, approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approval of a reverse stock split of common stock at a ratio ranging from 1:2 to 1:40 at the board's discretion. Additionally, the Proxy Statement proposes to adjourn the Annual Meeting to a later date if necessary to permit further solicitation of proxies. The Proxy Statement replaces the Original Proxy Statement filed on April 29, 2024, and includes updated information regarding the annual meeting, which may be held virtually if in-person attendance is not possible or advisable. The company has advised stockholders to vote their shares by proxy prior to the Annual Meeting.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more